EXHIBIT 12.1

ARIAD Pharmaceuticals, Inc.
Computation of Ratio/Deficiency of Earnings to Fixed Charges

($ in thousands)

																Nine Months
																Ended
	Year Ended December 31,															September 30,
	2006			2007			2008			2009			2010			2011
Earnings (loss):
Pretax income from continuing operations	$	(61,928	)	$	(58,522	)	$	(71,052	)	$	(80,008	)	$	85,248		$	(71,801	)
Fixed charges (from below)		606			481			705			439			341			244
Amortization of capitalized interest		14			14			0			0			0			0
Interest capitalized		0			0			0			0			0			0
Total earnings (loss)	$	(61,308	)	$	(58,027	)	$	(70,347	)	$	(79,569	)	$	85,589		$	(71,557	)
Fixed charges:
Interest expensed	$	483		$	337		$	550		$	287		$	206		$	172
Interest capitalized		0			0			0			0			0			0
Interest portion of rent expense		123			144			155			152			135			72
	$	606		$	481		$	705		$	439		$	341		$	244
Coverage deficiency (excess)	$	61,914		$	58,508		$	71,052		$	80,008		$	(85,248	)	$	71,801
Estimate of interest in rental expense:
Base rent expense	$	1,671		$	1,955		$	2,098		$	2,098		$	2,070		$	1,523
Incremental borrowing rate		7.38	%		7.38	%		7.38	%		7.23	%		6.50	%		4.75	%
	$	123		$	144		$	155		$	152		$	135		$	72

Ratio of earnings to fixed charges for year ended December 31, 2010: $85,589/$341= 251